Cargando…

A Systematic Review of Sildenafil Mortality Through the Years

Sildenafil is a medication used for the treatment of erectile dysfunction. It was approved by the U.S. Food and Drug Administration (FDA) in 1998. Several articles have raised concerns regarding the use of sildenafil and the occurrence of serious adverse events, such as myocardial ischemia, stroke,...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Ibrahim, Abdullah H, Ghallab, Khalid Q, Alhumaid, Fatima I, Almahfoudh, Husain H, Almadan, Ali J, Al Eid, Mohammed A, AlMishqab, Mujtaba H, Alsaffar, Mohammed F, Aljamea, Jawad H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719720/
https://www.ncbi.nlm.nih.gov/pubmed/36474651
http://dx.doi.org/10.7759/cureus.32179
_version_ 1784843388613296128
author Al Ibrahim, Abdullah H
Ghallab, Khalid Q
Alhumaid, Fatima I
Almahfoudh, Husain H
Almadan, Ali J
Al Eid, Mohammed A
AlMishqab, Mujtaba H
Alsaffar, Mohammed F
Aljamea, Jawad H
author_facet Al Ibrahim, Abdullah H
Ghallab, Khalid Q
Alhumaid, Fatima I
Almahfoudh, Husain H
Almadan, Ali J
Al Eid, Mohammed A
AlMishqab, Mujtaba H
Alsaffar, Mohammed F
Aljamea, Jawad H
author_sort Al Ibrahim, Abdullah H
collection PubMed
description Sildenafil is a medication used for the treatment of erectile dysfunction. It was approved by the U.S. Food and Drug Administration (FDA) in 1998. Several articles have raised concerns regarding the use of sildenafil and the occurrence of serious adverse events, such as myocardial ischemia, stroke, and even death. Our aim is to systematically review the existing literature on mortality associated with sildenafil use. The method used for this systematic review was completed by searching three databases: PubMed, Scopus, and Web of Science. Articles were screened and assessed for eligibility. This review uses the articles found to address the concerns associated with sildenafil and mortality. A total of 19 reports were used in our systematic review, in which there were 10 case reports, two case series, three systematic reviews, one narrative review, one retrospective study, one article in the British Medical Journal, and one commentary article. One FDA article in particular included case reports and reports to the FDA on the use of sildenafil eight months after its introduction to the market in 1998, with 522 deaths reported. Another retrospective study examined the use of sildenafil on infants below the age of 1 who did not have congenital heart disease but did suffer from severe pulmonary hypertension. The study found a mortality rate of 29%, which increased with sildenafil dosage. A case series examined six deaths related to non-prescription use of sildenafil. All these cases were subjected to autopsies and related to sexual activity. The study suggests that phosphodiesterase 5 inhibitors induced the deaths, and the concentration of sildenafil in the femoral blood was found to be between 0.032and0.087 μg. To conclude, the literature available on this topic is deemed insufficient to provide enough data to establish a direct link of causality between sildenafil and mortality. Although some studies paint sildenafil as the culprit behind these deaths, further studies and research are needed to explain the unexpected deaths following sildenafil use.
format Online
Article
Text
id pubmed-9719720
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-97197202022-12-05 A Systematic Review of Sildenafil Mortality Through the Years Al Ibrahim, Abdullah H Ghallab, Khalid Q Alhumaid, Fatima I Almahfoudh, Husain H Almadan, Ali J Al Eid, Mohammed A AlMishqab, Mujtaba H Alsaffar, Mohammed F Aljamea, Jawad H Cureus Pathology Sildenafil is a medication used for the treatment of erectile dysfunction. It was approved by the U.S. Food and Drug Administration (FDA) in 1998. Several articles have raised concerns regarding the use of sildenafil and the occurrence of serious adverse events, such as myocardial ischemia, stroke, and even death. Our aim is to systematically review the existing literature on mortality associated with sildenafil use. The method used for this systematic review was completed by searching three databases: PubMed, Scopus, and Web of Science. Articles were screened and assessed for eligibility. This review uses the articles found to address the concerns associated with sildenafil and mortality. A total of 19 reports were used in our systematic review, in which there were 10 case reports, two case series, three systematic reviews, one narrative review, one retrospective study, one article in the British Medical Journal, and one commentary article. One FDA article in particular included case reports and reports to the FDA on the use of sildenafil eight months after its introduction to the market in 1998, with 522 deaths reported. Another retrospective study examined the use of sildenafil on infants below the age of 1 who did not have congenital heart disease but did suffer from severe pulmonary hypertension. The study found a mortality rate of 29%, which increased with sildenafil dosage. A case series examined six deaths related to non-prescription use of sildenafil. All these cases were subjected to autopsies and related to sexual activity. The study suggests that phosphodiesterase 5 inhibitors induced the deaths, and the concentration of sildenafil in the femoral blood was found to be between 0.032and0.087 μg. To conclude, the literature available on this topic is deemed insufficient to provide enough data to establish a direct link of causality between sildenafil and mortality. Although some studies paint sildenafil as the culprit behind these deaths, further studies and research are needed to explain the unexpected deaths following sildenafil use. Cureus 2022-12-04 /pmc/articles/PMC9719720/ /pubmed/36474651 http://dx.doi.org/10.7759/cureus.32179 Text en Copyright © 2022, Al Ibrahim et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Al Ibrahim, Abdullah H
Ghallab, Khalid Q
Alhumaid, Fatima I
Almahfoudh, Husain H
Almadan, Ali J
Al Eid, Mohammed A
AlMishqab, Mujtaba H
Alsaffar, Mohammed F
Aljamea, Jawad H
A Systematic Review of Sildenafil Mortality Through the Years
title A Systematic Review of Sildenafil Mortality Through the Years
title_full A Systematic Review of Sildenafil Mortality Through the Years
title_fullStr A Systematic Review of Sildenafil Mortality Through the Years
title_full_unstemmed A Systematic Review of Sildenafil Mortality Through the Years
title_short A Systematic Review of Sildenafil Mortality Through the Years
title_sort systematic review of sildenafil mortality through the years
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719720/
https://www.ncbi.nlm.nih.gov/pubmed/36474651
http://dx.doi.org/10.7759/cureus.32179
work_keys_str_mv AT alibrahimabdullahh asystematicreviewofsildenafilmortalitythroughtheyears
AT ghallabkhalidq asystematicreviewofsildenafilmortalitythroughtheyears
AT alhumaidfatimai asystematicreviewofsildenafilmortalitythroughtheyears
AT almahfoudhhusainh asystematicreviewofsildenafilmortalitythroughtheyears
AT almadanalij asystematicreviewofsildenafilmortalitythroughtheyears
AT aleidmohammeda asystematicreviewofsildenafilmortalitythroughtheyears
AT almishqabmujtabah asystematicreviewofsildenafilmortalitythroughtheyears
AT alsaffarmohammedf asystematicreviewofsildenafilmortalitythroughtheyears
AT aljameajawadh asystematicreviewofsildenafilmortalitythroughtheyears
AT alibrahimabdullahh systematicreviewofsildenafilmortalitythroughtheyears
AT ghallabkhalidq systematicreviewofsildenafilmortalitythroughtheyears
AT alhumaidfatimai systematicreviewofsildenafilmortalitythroughtheyears
AT almahfoudhhusainh systematicreviewofsildenafilmortalitythroughtheyears
AT almadanalij systematicreviewofsildenafilmortalitythroughtheyears
AT aleidmohammeda systematicreviewofsildenafilmortalitythroughtheyears
AT almishqabmujtabah systematicreviewofsildenafilmortalitythroughtheyears
AT alsaffarmohammedf systematicreviewofsildenafilmortalitythroughtheyears
AT aljameajawadh systematicreviewofsildenafilmortalitythroughtheyears